312 related articles for article (PubMed ID: 29909881)
1. Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma.
Gray LA; Hernández Alava M; Wailoo AJ
Value Health; 2018 Jun; 21(6):748-757. PubMed ID: 29909881
[TBL] [Abstract][Full Text] [Related]
2. Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data.
Neilson AR; Jones GT; Macfarlane GJ; Pathan EM; McNamee P
Eur J Health Econ; 2022 Nov; 23(8):1357-1369. PubMed ID: 35113270
[TBL] [Abstract][Full Text] [Related]
3. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.
Hernández Alava M; Wailoo AJ; Ara R
Value Health; 2012 May; 15(3):550-61. PubMed ID: 22583466
[TBL] [Abstract][Full Text] [Related]
4. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
Moore A; Young CA; Hughes DA
Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
[TBL] [Abstract][Full Text] [Related]
5. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
6. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.
Hernández Alava M; Wailoo A; Pudney S; Gray L; Manca A
Health Technol Assess; 2020 Jun; 24(34):1-68. PubMed ID: 32613941
[TBL] [Abstract][Full Text] [Related]
7. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
8. Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings.
Shiroiwa T; Noto S; Fukuda T
Value Health; 2021 Aug; 24(8):1193-1202. PubMed ID: 34372985
[TBL] [Abstract][Full Text] [Related]
9. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
10. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
[TBL] [Abstract][Full Text] [Related]
11. Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.
Gray LA; Wailoo AJ; Hernandez Alava M
Value Health; 2018 Dec; 21(12):1399-1405. PubMed ID: 30502783
[TBL] [Abstract][Full Text] [Related]
12. Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs).
Kaambwa B; Chen G; Ratcliffe J; Iezzi A; Maxwell A; Richardson J
Pharmacoeconomics; 2017 Jan; 35(1):111-124. PubMed ID: 27557995
[TBL] [Abstract][Full Text] [Related]
13. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
Meregaglia M; Borsoi L; Cairns J; Tarricone R
Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
[TBL] [Abstract][Full Text] [Related]
14. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values.
Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N
Value Health; 2017; 20(7):945-952. PubMed ID: 28712624
[TBL] [Abstract][Full Text] [Related]
15. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR; Sun H; Barnett PG; Bansback N; Griffin SC; Bayoumi AM; Anis AH; Sculpher M; Cameron W; Brown ST; Holodniy M; Owens DK
MDM Policy Pract; 2017; 2(2):2381468317716440. PubMed ID: 30288427
[No Abstract] [Full Text] [Related]
16. A vision 'bolt-on' increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery.
Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
Eur J Health Econ; 2020 Jun; 21(4):501-511. PubMed ID: 31902023
[TBL] [Abstract][Full Text] [Related]
17. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
19. Mapping the PHQ-8 to EQ-5D, HUI3 and SF6D in patients with depression.
Abdin E; Chong SA; Seow E; Tan KB; Subramaniam M
BMC Psychiatry; 2021 Sep; 21(1):451. PubMed ID: 34517871
[TBL] [Abstract][Full Text] [Related]
20. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]